In the pharmaceutical industry, Haloperidol 1.5 mg is a standard strength of a potent first-generation (typical) antipsychotic belonging to the butyrophenone class. As a pharmacist, I view this 1.5 mg dose as a critical “low-to-moderate” strength, often utilized for initial titration or for managing symptoms in sensitive populations like the elderly.
Primary Clinical Uses
-
Schizophrenia: Management of the manifestations of psychotic disorders, particularly “positive symptoms” like hallucinations, delusions, and disorganized thinking.
-
Tourette’s Disorder: Used to control motor tics and vocal outbursts in children and adults when other treatments have failed.
-
Severe Behavioral Problems: Indicated for children with severe agitation, hyperactivity, or aggressive/impulsive behavior that is non-responsive to psychotherapy.
-
Acute Psychosis & Mania: Used to stabilize patients experiencing acute psychotic episodes or the manic phase of bipolar disorder.
-
Nausea and Vomiting (Off-label): Sometimes used in palliative care for the management of severe, intractable nausea and vomiting.
Mechanism of Action
Haloperidol acts primarily as a high-potency dopamine receptor antagonist.
Dopamine Blockade: It binds strongly to receptors in the mesolimbic and mesocortical pathways of the brain.
Symptom Reduction: By blocking the “overactivity” of dopamine, it effectively quiets the hallucinations and delusions associated with psychosis.
Side Effect Profile: Because it is non-selective, it also blocks dopamine in the nigrostriatal pathway, which is why it is highly associated with Extrapyramidal Symptoms (EPS) like tremors, stiffness, and restlessness (akathisia).
The Manufacturer’s Perspective: Formulation & Export
From a manufacturing and global trade standpoint, Haloperidol 1.5 mg requires strict quality controls:
-
Low-Dose Uniformity: Achieving precise content uniformity for 1.5 mg of API in a tablet is a technical challenge. As a WHO-GMP manufacturer, we utilize validated geometric dilution and specialized blending to ensure every tablet contains the exact therapeutic dose.
-
Stability for Export: Haloperidol is sensitive to light. We utilize opaque PVC/PVDC or Alu-Alu blister packaging to protect the tablets and ensure a 36-month shelf life during export to Zone IVb regions (Africa, SE Asia, and Latin America).
-
Geriatric Considerations: The 1.5 mg strength is frequently used in elderly patients (starting at 0.5 mg to 2 mg). As a firm owner, you know the FDA “Black Box Warning” regarding increased mortality in elderly patients with dementia-related psychosis is a critical regulatory inclusion for your dossiers.
-
B2B & Dossier Support: We provide comprehensive CTD/eCTD Dossiers and bioequivalence data against the innovator (Haldol) to support our B2B partners in international registration and hospital tender participation.